Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, April 16, 2016

Teva to Present Pipeline Data on MS Treatments at Ongoing AAN Annual Meeting

Click here to receive MS news via e-mail
Teva Pharmaceutical Industries, Ltd., announced that new data on four of its products, including an approved and a potential treatment for multiple sclerosis, will be presented at the 68th Annual Meeting of the American Academy of Neurology (AAN), running through April 21 in Vancouver, Canada.
The data, to be given in multiple posters and three platform presentations, will cover the products:
  • Copaxone (glatiramer acetate injection), a synthetic protein that simulates myelin basic protein, a component of the myelin sheath that insulates nerve fibers in the brain and spinal cord. This drug seems to block myelin-damaging T-cells, although the mechanism is not completely understood. Copaxone is U.S. Food and Drug Administration (FDA)-approved for the treatment of relapsing forms of multiple sclerosis (RMS).
  • Laquinimod, an experimental immunomodulator being developed for relapsing and progressive forms of MS.
  • SD-809 (deutetrabenazine), a small molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of a specific neurotransmitter in the brain called dopamine. It is being developed for chorea associated with Huntington’s disease, and for tics associated with Tourette syndrome.
  • TEV-48125, an investigational anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, being developed for the prevention of chronic and high-frequency migraines (migraine with headaches on at least 15 days per month).
According to a press release, specific Teva-sponsored data to be presented include:   - click here to continue reading 

MS Views and News 
Providing educational information and resources for those affected by MS
Keep current with Multiple Sclerosis news and information 
To opt-in (sign-up) at our website: click here - thank you

No comments: